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into lethally irradiated BALB/c mice along with 1  107 T cell
depleted bone marrow cells and 1  105 puriﬁed BCL1 cells (a
BALB/c-origin leukemia/lymphoma cell line). As a negative con-
trol, T cell depleted bone marrow alone rescued all lethally irra-
diated recipients and all survived more than 100 days after trans-
plantation without GVHD. All the recipients of T cell depleted
bone marrow and BCL1 cells developed tumor and died within 21
days post transplantation. Addition of 1  103 T cells in the graft
protected one out of ﬁve animals from developing tumor. Addition
of 1  104 T cells protected all recipients from developing tumor
and all survived more than 100 days after transplantation without
GVHD. Addition of both 1  105 and 1  106 protected all
animals from developing tumor. However, all animals in these two
groups developed GVHD and the majority died before 50 days
post transplantation. These data directly demonstrate that unma-
nipulated T cells alone can mediate GVL effect without causing
GVHD in a given animal model using a carefully titrated dose.
Based on these data, one can envision that separation of GVL from
GVHD may be achievable in a selected model by any approach
that is able to inhibit T cell function to a certain degree, speciﬁcally
or non-speciﬁcally. Knowledge of this information is important in
all animal models testing different approaches for the prevention of
GVHD without loss of GVL. Unfortunately, separation of GVL
from GVHD is very difﬁcult to achieve in humans by using
unmanipulated T cells alone due to unknown minimum dose
required for induction of GVHD in individual patients. Therefore,
in order to translate the ﬁndings into human setting, it will be
important to determine not only whether separation of GVL from
GVHD is achievable but also how wide the therapeutic window is.
The therapeutic window will help to determine whether the ap-
proach is translatable in humans or not.






SurvivalDay 21 Day 98
TCD BM alone — 18.6  0.9 19.1  2.1 5/5
TCDBM BCL1 5/5 14.7  0.8* — 0/5
1  103 4/5 16.7  2.1* 15.0  0.0 1/5
1  104 0/5 18.5  1.1* 18.7  2.0 5/5
1  105 0/5 15.7  1.6* 14.7  3.2* 2/5
1  106 0/5 14.9  0.9* — 0/5
*P 
 0.05, compared with TCD BM alone.
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CC CHEMOKINE RECEPTOR 2 IS INVOLVED IN INTESTINAL HOMING OF
ALLOREACTIVE DONOR CD8 T CELLS DURING GVHD
Terwey, T.H.; Kochman, A.A.; Eng, J.M.; Hubbard, V.M.; Muriglan,
S.J.; Waldman, E.D.; Zakrzewski, J.L.; Alpdogan, O.; van den Brink,
M.R.M. Memorial Sloan-Kettering Cancer Center, New York, NY.
Chemokines and chemokine receptors play an important role in
T cell homing and T cell mediated diseases, such as graft-versus-
host disease (GVHD). In a series of experiments using DNA
microarrays and ELISA analysis we found that monocyte chemoat-
tractant protein-1 (MCP-1) is upregulated in GVHD target organs
in the ﬁrst two weeks after bone marrow transplantation (BMT).
CC Chemokine Receptor 2 (CCR2) is the primary receptor for
MCP-1 and is expressed on a variety of hematopoietic cells includ-
ing monocytes, macrophages and memory T cells. The relevance
of CCR2 for homing of monocytes and macrophages has been
demonstrated in a variety of disease models but data on the rele-
vance of CCR2 for T cell homing are limited. Therefore, we
analyzed the effects of CCR2-deﬁciency on the homing capacity of
donor T cells in clinically relevant murine GVHD models. We
ﬁrst demonstrated that proliferation, alloactivation, IFN- produc-
tion and cytotoxicity of B6.CCR2/T cells were intact. However,
preliminary studies with a donor T cell inoculum consisting of
50% B6.WT and 50% B6.CCR2/ T cells showed a reduced
inﬁltration of B6.CCR2/ donor CD8 T cells into the intestinal
epithelium of C3FeB6F1 recipients. Homing to other organs and
homing of CD4 T cells was not impaired. In accordance with
these ﬁndings we could demonstrate a reduction of GVHD mor-
bidity and mortality in recipients of B6.CCR2/ CD8 T cells
while preliminary data showed no major difference for CD4 T
cells. Recipients of B6.CCR2/ CD8 T cells had a signiﬁcant
reduction in large intestine histopathology scores and showed a
trend towards lower scores for the small intestine. Moreover, the
graft-versus-tumor (GVT) activity of B6.CCR2/ CD8 T cells
against P815 mastocytoma in B6D2F1 recipients was intact, as
demonstrated by in vivo bioluminescent imaging. Again GVHD
mortality was reduced for B6D2F1 recipients of B6.CCR2/
CD8 T cells. In conclusion, our data suggest that the MCP-1-
CCR2 pathway is involved in intestinal homing of alloreactive T
cells during GVHD but is not essential for GVT activity.
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RISK FACTORS FOR THE DEVELOPMENT OF ACUTE AND CHRONIC
GVHD AFTER ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLAN-
TATION IN CHILDREN AND ADOLESCENTS
Peters, C.1; Lawitschka, A.1; Atarbaschi, A.1; Fritsch, G.2; Lion, T.2;
Rosenmayr, A.3; Fischer, G.4; Hoecker, P.4; Gadner, H.1; Matthes-
Martiin, S.1 1. St. Anna Children’s Hospital, Vienna, Austria; 2.
Children Cancer Research Institute, Vienna, Austria; 3. Austrian Stem
Cell Registry, Vienna, Austria; 4. University Clinic for Blood Group
Serology and Transfusion Medicine, Vienna, Austria.
Children and adolescents undergoing hematopoietic SCT have
to be protected from the deteriorating side effects of severe acute
and chronic GvHD which impairs quality of life and causes severe
long lasting acute and late effects. To analyse which risk factors are
of importance for the development of GvHD in young patients we
analysed 297 pediatric recipients of allogeneic stem cell transplants
at a single centre between 1993 and 2003. We evaluated the
inﬂuence of patient/donor sex, age, CMV status, disease and dis-
ease status, donor type, graft manipulation, use of monoclonal
antibodies or ATG, conditioning regimen, HLA-matching tech-
niques, year of transplantation and the number and source of
transplanted stem cells. The results showed an association of dis-
ease status (advanced malignancies vs. early stages), donor type
(unrelated vs. sibling), year of SCT (before vs. after 1997) and
HLA-typing methods (high resolution techniques vs. serological
typing) with an increased relative risk (RR) of aGvHD. Increased
risk of cGvHD was associated with non T-cell depleted (TCD)
PBSCT from UD, patient’s age 15 years, transplantation before
1997 and evidence of aGvHD. No signiﬁcant inﬂuence for the
development of aGvHD/cGvHD was found for TBI vs non TBI-
containing regimen, use of ATG, or myeloablative vs. non myeloa-
blative conditioning regimen, respectively. Furthermore, donor’s
age, gender, underlying disease (malignant vs. non malignant dis-
orders) and number of transplanted stem cells did not signiﬁcantly
inﬂuence the severity of aGVHD/cGVHD. However, in a Cox
Regression analysis with time dependent covariates treatment re-
lated mortality was higher in patients with malignancies when
transplanted at an advanced disease status or in CMV- IgG pos pts
receiving stem cells from a CMV-negative donor. Interestingly,
the overall and disease free survival in pts with malignant diseases
was similar with no, mild or severe aGvHD (5-yrs pSU: 0.67, 0.74
and 0.65) Our data support the preferential selection of CMV-pos
donors for CMV-pos recipients and the consideration of HLA-
typing with high resolution techniques to apply an appropriate
GvHD-prophylaxis according to the identiﬁed HLA disparities.
Furthermore, patients with high risk leukemia might beneﬁt from
allogeneic SCT at an early remission stage. Children with non-
malignant disorders can be treated with reduced intensity condi-
tioning without signiﬁcant higher risk of acute or chronic GvHD,
respectively.
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